Intensity Therapeutics

aka Intensity Therapeutics, Inc., NASDAQ:INTS

Intensity Therapeutics is a Connecticut biotech whose INT230-6 is injected straight into tumours with a penetration enhancer that spreads chemotherapy through the whole mass and triggers an immune response.

Intensity Therapeutics developed INT230-6, an intratumoural formulation of cisplatin and vinblastine with the amphiphilic molecule SHAO, which disperses the drugs through the tumour and into cells. Killing the tumour in place releases antigens that prime systemic immunity. The company is running the phase 3 INVINCIBLE-3 trial in soft tissue sarcoma and the phase 2 INVINCIBLE-4 trial in presurgical triple-negative breast cancer.

Headquarters

Shelton, Connecticut, US

Scorecard

All companies

#362of 1181 companies, score 9

phase 3 +3
modalities +2
registry trials +4

0 approved, 1 in phase 3, 0 earlier, 0 targets, 4 registry studies. Formula on the scorecards page.

Type

biotech · NASDAQ:INTS

Stage

Public

Website

www.intensitytherapeutics.com/

Founded

2012

Products

1top

Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)

INT230-6

INT230-6 is an experimental investigational agent whose form is not stated in the registry from Intensity Therapeutics in phase 3 trials for sarcomas, with its target not yet stated publicly.

Connected